Annexon, Inc. (NASDAQ:ANNX) Given Average Recommendation of "Buy" by Analysts

Shares of Annexon, Inc. (NASDAQ:ANNX - Get Free Report) have been assigned an average rating of "Buy" from the six brokerages that are covering the firm, Marketbeat reports. Six investment analysts have rated the stock with a buy recommendation. The average 12-month price objective among brokers that have issued a report on the stock in the last year is $15.80.

A number of equities research analysts recently issued reports on the company. Needham & Company LLC restated a "buy" rating and issued a $16.00 price objective on shares of Annexon in a research note on Friday, November 15th. HC Wainwright reissued a "buy" rating and issued a $30.00 price target on shares of Annexon in a research report on Tuesday, December 17th. Finally, Cantor Fitzgerald reaffirmed an "overweight" rating on shares of Annexon in a report on Friday, November 15th.

Annexon Price Performance

Shares of ANNX traded up $0.17 during mid-day trading on Friday, hitting $2.87. The stock had a trading volume of 1,090,278 shares, compared to its average volume of 1,399,867. The firm has a market cap of $305.38 million, a P/E ratio of -2.73 and a beta of 1.07. Annexon has a 52 week low of $2.64 and a 52 week high of $8.40. The business has a fifty day moving average price of $4.41 and a 200-day moving average price of $5.63.

Institutional Trading of Annexon

Several institutional investors and hedge funds have recently bought and sold shares of the company. BNP Paribas Financial Markets purchased a new stake in shares of Annexon in the fourth quarter worth $59,000. CANADA LIFE ASSURANCE Co purchased a new stake in shares of Annexon in the 4th quarter valued at about $77,000. E Fund Management Co. Ltd. boosted its position in shares of Annexon by 36.0% during the 4th quarter. E Fund Management Co. Ltd. now owns 15,447 shares of the company's stock valued at $79,000 after acquiring an additional 4,086 shares during the last quarter. Forefront Analytics LLC grew its holdings in shares of Annexon by 56.8% during the fourth quarter. Forefront Analytics LLC now owns 16,433 shares of the company's stock worth $84,000 after purchasing an additional 5,950 shares in the last quarter. Finally, KLP Kapitalforvaltning AS bought a new position in shares of Annexon in the fourth quarter worth approximately $98,000.

Annexon Company Profile

Annexon, Inc, a clinical-stage biopharmaceutical company, discovers and develops medicines for treating inflammatory-related diseases. Its lead candidate is ANX005, an investigational full-length monoclonal antibody, which is in Phase 3 clinical trial for the treatment of patients with guillain-barré syndrome; completed Phase II clinical trial for treating Huntington's disease; and in Phase II clinical trial for the treatment of amyotrophic lateral sclerosis.